FibroGen Inc. Q2 2024 Update

TL;DR

FibroGen Q2 2024: Financials show US Gov Bonds, preferred stock. Key partnerships with Astellas, AstraZeneca.

AI Summary

FibroGen Inc. reported its second quarter 2024 results, ending June 30, 2024. The company's financial statements reflect various financial activities and investments, including US Government Bonds valued at fair value and non-redeemable preferred stock. Key agreements and partnerships mentioned include those with Astellas, AstraZeneca AB, and Novaquest Capital Management.

Why It Matters

This filing provides insight into FibroGen's financial health and ongoing business relationships, which can impact its stock performance and future development of pharmaceutical products.

Risk Assessment

Risk Level: medium — The company operates in the pharmaceutical sector, which is subject to significant regulatory and market risks, and the filing details various financial instruments and agreements that carry inherent risks.

Key Numbers

• 20240630 — Report End Date (Indicates the period covered by the financial statements.)
• 20240806 — Filing Date (Date the report was officially submitted to the SEC.)

Key Players & Entities

• FibroGen Inc. (company) — Filer of the 10-Q report
• Astellas (company) — Partner mentioned in the filing
• AstraZeneca AB (company) — Partner mentioned in the filing
• Novaquest Capital Management (company) — Entity involved in a Revenue Interest Financing Agreement
• US Government Bonds (dollar_amount) — Financial asset held by the company

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value FGEN The Nasdaq Global Se

Filing Documents

• fgen-20240630.htm (10-Q) — 3101KB
• fgen-ex10_2.htm (EX-10.2) — 574KB
• fgen-ex10_3.htm (EX-10.3) — 1015KB
• fgen-ex10_4.htm (EX-10.4) — 85KB
• fgen-ex10_5.htm (EX-10.5) — 109KB
• fgen-ex31_1.htm (EX-31.1) — 9KB
• fgen-ex31_2.htm (EX-31.2) — 9KB
• fgen-ex32_1.htm (EX-32.1) — 9KB
• img86529339_0.jpg (GRAPHIC) — 13KB
• img86529339_1.jpg (GRAPHIC) — 7KB
• 0000950170-24-091808.txt ( ) — 13372KB
• fgen-20240630.xsd (EX-101.SCH) — 1689KB
• fgen-20240630_htm.xml (XML) — 1896KB

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements 2 Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023 (Unaudited) 2 Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2024 and 2023 (Unaudited) 3 Condensed Consolidated Statements of Comprehensive Loss for the Three and Six Months Ended June 30, 2024 and 2023 (Unaudited) 4 Condensed Consolidated Statements of Changes in Stockholders' Deficit for the Three and Six Months Ended June 30, 2024 and 2023 (Unaudited) 5 Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2024 and 2023 (Unaudited) 7 Notes to the Condensed Consolidated Financial Statements (Unaudited) 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 27 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 45 Item 4.

Controls and Procedures

Controls and Procedures 45

—OTHER INFORMATION

PART II—OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 46 Item 1A.

Risk Factors

Risk Factors 46 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 82 Item 3. Defaults Upon Senior Securities 82 Item 4. Mine Safety Disclosures 82 Item 5. Other Information 82 Item 6. Exhibits 83

Signatures

Signatures 84 1 Table of Contents FIBROGEN, INC.

—FINANCIA L INFORMATION

PART I—FINANCIA L INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS CONDENSED CONSOLIDA TED BALANCE SHEETS (In thousands, except per share amounts) (Unaudited) June 30, 2024 December 31, 2023 Assets Current assets: Cash and cash equivalents $ 140,714 $ 113,688 Short-term investments — 121,898 Accounts receivable, net ($ 4,178 and $ 6,079 from related parties) 6,412 12,553 Inventories 25,397 41,565 Prepaid expenses and other current assets 36,936 41,855 Total current assets 209,459 331,559 Restricted time deposits 1,658 1,658 Property and equipment, net 10,917 13,126 Equity method investment in unconsolidated variable interest entity 6,912 5,290 Operating lease right-of-use assets 61,212 68,093 Other assets 3,045 3,803 Total assets $ 293,203 $ 423,529 Liabilities, redeemable non-controlling interests and deficit Current liabilities: Accounts payable ($ 1,586 and $ 0 to a related party) $ 9,938 $ 17,960 Accrued and other current liabilities ($ 10,993 and $ 39,814 to a related party) 113,574 172,891 Deferred revenue ($ 6,111 and $ 7,220 to related parties) 9,546 12,740 Operating lease liabilities, current 15,531 14,077 Total current liabilities 148,589 217,668 Product development obligations 17,397 17,763 Deferred revenue, net of current ($ 3,292 and $ 9,705 to a related party) 131,192 157,555 Operating lease liabilities, non-current 58,376 66,537 Senior secured term loan facilities, non-current 72,478 71,934 Liability related to sale of future revenues, non-current 54,532 51,413 Other long-term liabilities ($ 605 and $ 656 to a related party) 1,012 2,858 Total liabilities 483,576 585,728 Commitments and Contingencies Redeemable non-controlling interests 21,480 21,480 Stockholders' deficit: Preferred stock, $ 0.01 par value; 125,000 shares authorized; no shares issued and outstanding at June 30, 2024 and December 31, 2023

View Full Filing

View this 10-Q filing on SEC EDGAR